The Fraction of Rhinovirus Detections Attributable to Mild and Severe Respiratory Illness in a Setting of High Human Immunodeficiency Virus Prevalence, South Africa, 2013-2015.


Journal

The Journal of infectious diseases
ISSN: 1537-6613
Titre abrégé: J Infect Dis
Pays: United States
ID NLM: 0413675

Informations de publication

Date de publication:
05 05 2019
Historique:
received: 21 08 2018
accepted: 20 12 2018
pubmed: 28 12 2018
medline: 17 3 2020
entrez: 28 12 2018
Statut: ppublish

Résumé

The association of rhinovirus (RV) detection to illness is poorly understood. We enrolled case patients hospitalized with severe respiratory illness (SRI) at 2 hospitals and outpatients with influenza-like illness (ILI) and asymptomatic individuals (controls) from 2 affiliated clinics during 2013-2015. We compared the RV prevalence among ILI and SRI cases to those of controls stratified by human immunodeficiency virus (HIV) serostatus using penalized logistic regression. The attributable fraction (AF) was calculated. During 2013-2015, RV was detected in 17.4% (368/2120), 26.8% (979/3654), and 23.0% (1003/4360) of controls, ILI cases, and SRI cases, respectively. The RV AF (95% confidence interval) was statistically significant among children aged <5 years (ILI: 44.6% [30.7%-55.7%] and SRI: 50.3% [38.6%-59.9%]; P < .001) and individuals aged ≥5 years (ILI: 62.9% [54.4%-69.8%] and SRI: 51.3% [38.7%-61.3%]; P < .001) as well as among HIV-infected (ILI: 59.9% [45.8%-70.3%] and SRI: 39.8% [22.3%-53.3%]; P < .001) and HIV-uninfected (ILI: 53.6% [44.7%-61.1%] and SRI: 55.3% [45.6%-63.2%]; P < .001) individuals. Although RV detection was common among controls, it was also associated with a substantial proportion of clinical illness across age groups, irrespective of HIV status.

Sections du résumé

BACKGROUND
The association of rhinovirus (RV) detection to illness is poorly understood.
METHODS
We enrolled case patients hospitalized with severe respiratory illness (SRI) at 2 hospitals and outpatients with influenza-like illness (ILI) and asymptomatic individuals (controls) from 2 affiliated clinics during 2013-2015. We compared the RV prevalence among ILI and SRI cases to those of controls stratified by human immunodeficiency virus (HIV) serostatus using penalized logistic regression. The attributable fraction (AF) was calculated.
RESULTS
During 2013-2015, RV was detected in 17.4% (368/2120), 26.8% (979/3654), and 23.0% (1003/4360) of controls, ILI cases, and SRI cases, respectively. The RV AF (95% confidence interval) was statistically significant among children aged <5 years (ILI: 44.6% [30.7%-55.7%] and SRI: 50.3% [38.6%-59.9%]; P < .001) and individuals aged ≥5 years (ILI: 62.9% [54.4%-69.8%] and SRI: 51.3% [38.7%-61.3%]; P < .001) as well as among HIV-infected (ILI: 59.9% [45.8%-70.3%] and SRI: 39.8% [22.3%-53.3%]; P < .001) and HIV-uninfected (ILI: 53.6% [44.7%-61.1%] and SRI: 55.3% [45.6%-63.2%]; P < .001) individuals.
CONCLUSIONS
Although RV detection was common among controls, it was also associated with a substantial proportion of clinical illness across age groups, irrespective of HIV status.

Identifiants

pubmed: 30590585
pii: 5257995
doi: 10.1093/infdis/jiy725
pmc: PMC7804373
mid: NIHMS1659071
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

1697-1704

Subventions

Organisme : NCIRD CDC HHS
ID : U01 IP001048
Pays : United States
Organisme : NCIRD CDC HHS
ID : U51 IP000155
Pays : United States
Organisme : NCIRD CDC HHS
ID : U51 IP000528
Pays : United States

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Références

Influenza Other Respir Viruses. 2014 Sep;8(5):567-73
pubmed: 24990601
Clin Infect Dis. 2012 Apr;54 Suppl 2:S190-9
pubmed: 22403235
BMC Infect Dis. 2015 Feb 25;15:95
pubmed: 25879805
J Med Virol. 2012 Mar;84(3):536-42
pubmed: 22246843
PLoS One. 2011 Mar 29;6(3):e17780
pubmed: 21479259
Emerg Infect Dis. 2017 Jul;23(7):1124-1132
pubmed: 28628462
J Med Virol. 2010 Jul;82(7):1282-90
pubmed: 20513097
Pac Symp Biocomput. 2011;:106-17
pubmed: 21121038
J Infect Dis. 2012 Dec 15;206 Suppl 1:S159-65
pubmed: 23169964
CMAJ. 2015 Nov 17;187(17):1279-1284
pubmed: 26464137
J Infect Dis. 2016 Feb 15;213(4):584-91
pubmed: 26180044
J Infect Dis. 2013 Dec 15;208 Suppl 3:S217-26
pubmed: 24265481
J Med Virol. 2012 May;84(5):823-31
pubmed: 22431032
PLoS One. 2015 Dec 22;10(12):e0145447
pubmed: 26696249
J Clin Virol. 2016 Feb;75:21-6
pubmed: 26741826
J Infect Dis. 2014 Nov 15;210(10):1649-57
pubmed: 24907383
Emerg Infect Dis. 2013 Nov;19(11):1766-74
pubmed: 24209781
Emerg Infect Dis. 2015 Apr;21(4):600-8
pubmed: 25811455
Clin Infect Dis. 2014 May;58(9):1241-9
pubmed: 24567249
J Infect Dis. 2014 Jan 1;209(1):56-65
pubmed: 23922370

Auteurs

Orienka Hellferscee (O)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Florette K Treurnicht (FK)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.

Sibongile Walaza (S)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Mignon Du Plessis (M)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.

Anne Von Gottberg (A)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Nicole Wolter (N)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Jocelyn Moyes (J)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Halima Dawood (H)

Department of Medicine, Pietermaritzburg Metropolitan Hospital.
Department of Medicine, University of KwaZulu-Natal, Pietermaritzburg.

Ebrahim Variava (E)

Department of Medicine, Klerksdorp-Tshepong Hospital Complex, Klerksdorp.
Department of Medicine, Faculty of Health Sciences, Johannesburg, South Africa.
Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa.

Marthi Pretorius (M)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
Technical Research and Development, Novartis Pharma AG, Basel, Switzerland.

Marietjie Venter (M)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
Center for Viral Zoonoses, Department of Medical Virology, University of Pretoria, South Africa.

Cheryl Cohen (C)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg.

Stefano Tempia (S)

Centre for Respiratory Diseases and Meningitis, National Institute for Communicable Diseases of the National Health Laboratory Service, Johannesburg.
Influenza Division, Centers for Disease Control and Prevention, Atlanta, Georgia.
Influenza Program, Centers for Disease Control and Prevention, Pretoria, South Africa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH